SCP Vitalife

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

MST Medical Surgery Technologies Ltd., founded in 2005 and headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida, specializes in developing advanced image analysis software for the healthcare industry. The company is a leader in surgical analytics, focusing on medical robotics and computer-assisted surgery. Its flagship product, AutoLap, is an innovative robotic image-guided laparoscope positioning system that enhances the precision and control of surgical procedures by providing real-time guidance based on the surgeon's movements. Additionally, MST offers Surgical Training Analytics (STA), a tool designed to capture images from actual surgical procedures, aiding in the training of new surgeons. By leveraging advanced visualization, artificial intelligence, and machine learning, MST aims to transform the operating room with automated, data-driven solutions that improve outcomes for both surgeons and patients.

Sensible Medical Innovation Ltd, established in 2007 and based in Netanya, Israel, specializes in developing medical radar technology for monitoring and imaging. Its flagship product, ReDS, is designed to track and manage lung fluid in patients with heart failure and other fluid-related health issues, providing accurate and actionable data to healthcare professionals. This non-invasive solution aims to improve patient quality of life and potentially reduce hospital readmissions.

Lifeward is a medical device company based in Marlborough, Massachusetts, specializing in innovative solutions for individuals with lower limb disabilities. The company develops, manufactures, and markets advanced walking systems, notably the ReWalk Rehabilitation System and the ReWalk Personal System. The ReWalk Rehabilitation System is designed for use in rehabilitation centers, enabling users to walk, stand, sit, and navigate stairs. In contrast, the ReWalk Personal System is intended for everyday use, allowing individuals to engage in activities at home, work, and various outdoor environments. This system supports standing, sitting, and turning, while also facilitating stair climbing and descending. Lifeward's mission is to enhance the quality of life for those with spinal cord injuries by providing robotic technologies that offer significant functional and health benefits across different settings, including clinical environments and everyday life. The company operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

novoGI Inc. specializes in the design and development of device-driven solutions for managing gastrointestinal (GI) diseases. The company offers innovative nitinol-based compression anastomosis devices that facilitate the natural reconnection of the intestine after resections, such as those performed in colon cancer treatments. This technology represents a significant advancement in gastrointestinal surgery, as it leverages biological healing processes to enhance patient outcomes. novoGI, originally founded in 1996 as NiTi Surgical Solutions, changed its name in June 2012. The company is headquartered in Atlanta, Georgia, with additional European operations in Paris and research, development, and manufacturing facilities in Netanya, Israel. Its product line includes FDA-cleared and CE-marked disposable tissue closure devices that are designed to support effective healing in patients undergoing colorectal procedures.

Garnet BioTherapeutics is a clinical stage, venture-backed cell therapy company focused on dermal-based regenerative therapy.

Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

Beta-O2 Technologies Ltd. is a biomedical company based in Rosh HaAyin, Israel, specializing in the development of implantable bioreactors. The company designs the ßAir Bio-artificial Pancreas, aimed at treating and potentially curing type 1 diabetes (T1D). This innovative device addresses key challenges associated with islet cell transplantation, such as the need for lifelong immunosuppression and the declining functionality of transplanted cells due to inadequate oxygen supply. The ßAir, implanted through a minimally invasive procedure, creates a supportive environment for pancreatic islet cells, facilitating their growth and function. By providing oxygen proactively to the contained cells and ensuring full immune protection, the device allows patients to avoid insulin injections and reduces the risk of diabetes-related complications. Additionally, Beta-O2 Technologies is working on the ßAir Bio-artificial Adrenal to address adrenocortical insufficiency and related stress disorders.

GeneGrafts Ltd., also known as GreenGrafts Ltd., is a biotechnology company based in Haifa, Israel, specializing in the development of therapeutic products aimed at treating conditions such as cardiac arrhythmia, Parkinson's disease, and epilepsy. Founded in November 2003, the company has established a proprietary technology platform that employs cell therapy to modulate excitable tissues in the brain and heart. This innovative approach involves the transplantation of cell grafts derived from the patient's own body, which define the ion channels necessary for integrating with the target organ. By doing so, GeneGrafts seeks to alter the electrical properties of these organs in a controlled manner, providing a promising new avenue for the treatment of various neurological disorders and cardiac conditions.

Can-Fite BioPharma is an Israeli biopharmaceutical company engaged in the discovery and clinical development of therapeutics for cancer and inflammatory diseases. The company specializes in developing orally bioavailable small molecule drugs that target the A3 adenosine receptor (A3AR). Can-Fite's lead drug candidate, Piclidenoson, is currently in a Phase III trial aimed at treating psoriasis. Additionally, Namodenoson, another key product, is advancing into a Phase III trial for hepatocellular carcinoma, the most prevalent form of liver cancer, and is also undergoing a Phase IIb trial for non-alcoholic steatohepatitis. With a robust pipeline of proprietary compounds in advanced clinical stages, Can-Fite is focused on addressing significant unmet medical needs in autoimmune-inflammatory conditions and cancer.